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Abstract
Background: Molecular monitoring of parasite resistance has become an important complementary tool in
establishing rational anti-malarial drug policies. Community surveys provide a representative sample of the parasite
population and can be carried out more rapidly than accrual of samples from clinical cases, but it is not known
whether the frequencies of genetic resistance markers in clinical cases differ from those in the overall population,
or whether such community surveys can provide good predictions of treatment failure rates.
Methods: Between 2003 and 2005, in vivo drug efficacy of amodiaquine or chloroquine plus sulphadoxine-
pyrimethamine was determined at three sites in Papua New Guinea. The genetic drug resistance profile (i.e., 33
single nucleotide polymorphisms in Plasmodium falciparum crt, mdr1, dhfr, dhps, and ATPase6) was concurrently
assessed in 639 community samples collected in the catchment areas of the respective health facilities by using a
DNA microarray-based method. Mutant allele and haplotype frequencies were determined and their relationship
with treatment failure rates at each site in each year was investigated.
Results: PCR-corrected in vivo treatment failure rates were between 12% and 28% and varied by site and year with
variable longitudinal trends. In the community samples, the frequencies of mutations in pfcrt and pfmdr1 were
high and did not show significant changes over time. Mutant allele frequencies in pfdhfr were moderate and those
in pfdhps were low. No mutations were detected in pfATPase6. There was much more variation between sites than
temporal, within-site, variation in allele and haplotype frequencies. This variation did not correlate well with
treatment failure rates. Allele and haplotype frequencies were very similar in clinical and community samples from
the same site.
Conclusions: The relationship between parasite genetics and in vivo treatment failure rate is not straightforward.
The frequencies of genetic anti-malarial resistance markers appear to be very similar in community and clinical
samples, but cannot be used to make precise predictions of clinical outcome. Thus, indicators based on molecular
data have to be considered with caution and interpreted in the local context, especially with regard to prior drug
usage and level of pre-existing immunity. Testing community samples for molecular drug resistance markers is a
complementary tool that should help decision-making for the best treatment options and appropriate potential
alternatives.
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Background
The development and spread of Plasmodium falciparum
resistance to the most commonly used anti-malarial
drugs is a major challenge in the control of malaria [1].
Quantifying the level of drug resistance through regular
monitoring provides essential information to the health
authorities responsible for ensuring ready access to
effective drugs. Methods for assessing drug resistance in
malaria include in vivo drug efficacy studies (the gold
standard), in vitro sensitivity testing of patient isolates,
and surveys designed to detect molecular markers of
drug resistance. Each approach has advantages and dis-
advantages (discussed in [2-4]) and herein field data
evaluating the usefulness of the molecular marker
approach are presented.
Molecular screening to detect drug resistance was
made possible by studies identifying the genetic basis of
drug resistance in P. falciparum and this approach has
subsequently become an integral part for the evaluation
of resistance to treatment [5,6]. Chloroquine resistance
(CQR) is attributable to single nucleotide polymorph-
isms (SNPs) in pfcrt and pfmdr1 (reviewed in [7-9]).
Resistance to sulphadoxine-pyrimethamine (SP) is asso-
ciated with a stepwise accumulation of mutations in
pfdhfr and pfdhps (reviewed in [10]). Artemisinin deri-
vates have been shown to inhibit pfATPase6 [11] and
SNPs in pfATPase6 may become associated with resis-
tance in vitro [12,13]. It has also become apparent that
these mutations do not act in isolation, but often act
synergistically to encode or enhance resistance. Resis-
tance may arise through sequential accumulation of
mutations in a single gene, such as anti-folate resistance
in the pfdhfr gene [4,14]. Mutations in different genes
may also act synergistically. Linkage disequilibrium is
often observed between pfcrtK76T and pfmdr1N86Y in
vivo [15-17] and the commonly accepted hypothesis is
that CQR is mediated by multigenic processes [18], pri-
mary resistance being encoded by pfcrtK76T with SNPs
in pfmdr1 playing an important role in modulating
levels of CQR. The requirement to consider intra- and
inter-genic genotypes impose limitations on the use of
molecular methods such as PCR-RFLP which can iden-
tify the presence of mutations at individual markers, but
not individual malaria genotypes defined at multiple loci
in large sample sets.
The link between molecular markers and resistance
can be clearly demonstrated in the laboratory, but the
usefulness of these markers in the field has been contro-
versial, primarily because the strength of their associa-
tions with in vivo treatment outcome is not consistent
in different epidemiological settings. There are two plau-
sible reasons for this [3]. Firstly, drug failure may occur
for reasons other than parasite genetics. Patients may
take incomplete drug courses, may have poor drug
absorption or metabolism and so on. When marker fre-
quencies are low, these human sources of drug failure
may obscure the relationship between marker and resis-
tance. Secondly, most studies have primarily focused on
single genes and markers [19], rather than multiple mar-
kers which may act synergistically. A further limitation
is that most analyses of molecular markers have been
conducted as part of clinical studies and have, therefore,
been limited to sentinel sites with good access to health
care facilities and mostly examined clinical cases within
a restricted age group [20]. Moreover, most such studies
used parasite genetic measures based on the proportions
of patients carrying a given genetic marker, or compo-
site measures formed from ad hoc functions of such
proportions [5]. This ignores the fact that patients often
carry multiple clones of parasites and so may carry a
mutation even if most of their parasites are wild-type. In
principle, the evolution of drug resistance should be
assessed by genetic profiling of representative samples of
the circulating parasite population, which includes the
reservoir in asymptomatic carriers. This should be sum-
marized using population-genetic measures of allele fre-
quencies (for single alleles) and haplotype frequencies
(for multiple linked alleles). However, genetic data from
community samples have rarely been compared with in
vivo treatment responses [21,22]. In addition, it is not
clear whether the molecular profile of parasites in symp-
tomatic patients seen at health facilities matches that of
the large circulating parasite reservoir.
The current study has investigated the role and applic-
ability of the molecular drug resistance profiles in com-
munity samples for the monitoring of drug resistant
malaria in Papua New Guinea (PNG). For this purpose,
in vivo drug efficacy studies with the first-line regimen
of amodiaquine or chloroquine plus sulphadoxine-pyri-
methamine (AQ+SP or CQ+SP) were conducted at
three different sites. A DNA microarray-based technol-
ogy was used to compare the molecular drug resistance
profile in clinical samples and blood samples collected
in the communities from the catchment areas of the
corresponding health facilities. Finally, the relationships
of the allele and haplotype frequencies of the molecular
markers with the rates and time-trends in clinical failure
at the different sites were investigated.
Methods
Study areas and design
The three study sites in Papua New Guinea (PNG) were
1) the Sigimaru health centre (HC) in the Karimui area
(Simbu Province), 2) the Kunjingini HC in the South
Wosera area (East Sepik Province), and 3) the Mugil HC
in the North Coast area of Madang (Madang Province).
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In Karimui, a rural region in the highland fringe area of
PNG, the studies were run between October and April
in three consecutive years (2003, 2004, and 2005). In the
Wosera, located in the floodplain of the Sepik river in
the north-eastern part of the country bordering Indone-
sian Papua, the study period was between December
and June in 2003 and 2004. The study in the rainforest
area at the North Coast of Madang was conducted
between April 2004 and February 2005.
Malaria transmission is perennial with limited varia-
tions between wet (October to April) and dry (May to
September) season at all sites. Transmission intensity
in PNG decreases significantly with increasing altitude
[23] and is higher in the lowland regions of the
Wosera and the North Coast than in the Karimui area,
an elevated plateau situated at an altitude of 700 to
1,200 m. There is little socioeconomic stratification
between and within sites, although there are
differences in health care provision and drug use pat-
terns [24-28]. Baseline characteristics of the study sites
are summarized in Table 1.
Assessment of in vivo drug efficacy
Drug efficacy studies were conducted according to the
standardized WHO protocol for low to moderate trans-
mission areas [29] and are described in detail elsewhere
[30]. Patients were classified according to their clinical
and parasitological responses into early treatment failure
(ETF), late clinical failure (LCF), late parasitological fail-
ure (LPF), or adequate clinical and parasitological
response (ACPR) and crude failure rates were PCR-cor-
rected by comparing the msp2 (merozoite surface pro-
tein 2) genotyping patterns of paired Day 0 and
treatment failure samples [31]. Annual treatment failure
rates (TFR = ETF + LCF + LPF) of AQ+SP and CQ+SP
were pooled for the analysis in the current study.
Table 1 Characteristics of study sites and populations between 2003 and 2005
Karimui area
(Simbu Province)
South Wosera
(East Sepik Province)
North Coast
(Madang Province)
Endemicity* mesoendemic mesoendemic Mesoendemic
Transmission
intensity§
moderate high high
Year 2003 2004 2005 2003 2004 2004
n 265 347 359 317 366 359
Mean age in years
(95% CI, range)
18.9
(17.0-20.7, 0.5-60)
19.4
(17.7-21.2, 0.5-73)
15.4
(14.0-16.8, 0.5-66)
20.4
(18.7-22.2, 0.5-70)
21.3
(19.6-23.1, 0.5-69)
19.6
(17.8-21.5, 0.5-70)
Sex: females/n (%) 137/265 (51.7) 192/347 (55.3) 186/359 (51.9) 159/317 (50.1) 189/366 (51.6) 182/359 (50.7)
Mean temperature in°
C (95% CI)
36.1
(36.0-36.1)
36.1
(36.0-36.1)
36.4
(36.4-36.5)
36.6
(36.5-36.6)
36.5
(36.5-36.6)
36.4
(36.3-36.4)
Mean Hb in g/dl
(95% CI)
11.5
(11.2-11.8)
12.1
(11.8-12.3)
11.4
(11.2-11.7)
10.7
(10.5-10.9)
10.7
(10.6-10.9)
10.4
(10.3-10.6)
x/n (Pf prevalence by
microscopy
(%, 95% CI)
34/258
(13.2, 9.3-17.9)
64/346
(18.5, 14.5-23.0)
82/358
(22.9, 18.7-27.6)
55/314
(17.5, 13.5-22.2)
96/356
(27.0, 22.4-31.9)
82/358
(22.9, 18.7-27.6)
x/n (Pf prevalence by
msp2 nPCR
(%, 95% CI)
102/263
(38.8, 32.9-45.0)
71/347
(20.5, 16.3-25.1)
131/359
(36.5, 31.5-41.7)
129/317
(40.7, 35.2-46.3)
147/366
(40.2, 35.1-45.4)
115/359
(32.0, 27.2-37.1)
Mean multiplicity of
infection (MOI) (95%
CI, range)
1.46 (1.32-1.60, 1-4) 1.59 (1.38-1.80, 1-4) 1.77 (1.62-1.92, 1-4) 1.77 (1.57-1.96, 1-6) 1.85 (1.68-2.02, 1-5) 1.54 (1.38-1.70, 1-5)
* x/n (Pf prevalence
in age group 2-9 (%,
95% CI)
13/93
(14.0, 7.7-22.8)
20/107
(18.7, 11.8-27.4)
44/138
(31.9, 24.2-40.4)
21/98
(23.6, 15.2-33.8)
36/110
(32.7, 24.1-42.3)
46/128
(35.9, 27.7-44.9)
* Spleen rate in age
group 2-9
(95% CI)
nd 26.8
(18.8-36.2)
35.8
(27.7-44.6)
17.7
(10.2-27.4)
17.3
(10.7-25.7)
41.1
(32.4-50.3)
Number of patients
(in vivo drug efficacy
studies)#
97 93 128 112 115 104
Treatment Failure
Rate (TFR, %)#
27.8 18.3 16.4 16.1 21.7 11.5
* determined according to P. falciparum prevalence and spleen rates (i.e., proportion of individuals with enlarged spleen) of 11-50% in children aged 2-9 years
([29]);
§ ([242628]), n, total number of people surveyed; CI, confidence interval; Hb, haemoglobin; Pf, P. falciparum; msp2, merozoite surface protein 2; nPCR, nested
polymerase chain reaction; nd, not determined; # [3034]
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Community-based cross-sectional surveys
Cross-sectional surveys were conducted in the catchment
areas of each of the health centres using a randomized
household approach. To obtain a representative random
sample of the parasite population circulating in the corre-
sponding communities (i.e., approximately 100 PCR-posi-
tive P. falciparum samples from each location), between
300 and 350 blood specimens were collected per commu-
nity [27]. Overall, a total of 2,013 individuals from ran-
domly selected villages and households were recruited
for the community surveys between 2003 and 2005.
Apart from demographic characteristics, collected
information included history of sickness (onset, type and
duration of symptoms), health facility attendance, pur-
chase or consumption of drugs outside health facilities,
and anti-malarial treatment courses received in the pre-
ceding year (extracted from health books when avail-
able). Axillary temperature was measured with an
electronic thermometer and spleen size was assessed in
the recumbent position using Hackett’s grading system
[32]. Blood samples for parasitological examination by
microscopy, haemoglobin (Hb) level determination
(HemoCue®, Ångelholm, Sweden), and molecular identi-
fication of parasite genotypes were collected by vene-
puncture using 2 ml EDTA-Vacutainer™ tubes (BD
Biosciences, Allschwil, Switzerland). Plasma was sepa-
rated by centrifugation and red blood cell pellets were
stored frozen until further processing.
Molecular analyses
DNA was extracted using QIAamp® DNA Blood Kit
(Qiagen, Hombrechtikon, Switzerland) according to the
manufacturer’s instructions. Assessment of SNPs for
drug resistant malaria was done for pfmdr1 mutations
N86Y, Y184F, S1034C, N1042D and D1246Y, pfcrt
mutations K76T, H97Q, T152A, S163R, A220S, Q271E,
N326D/S, I356L/T and R371I, pfdhfr mutations A16V,
N51I, C59R, S108N/T and I164L, pfdhps mutations
S436A, A437G, K540E, A581G and A613T/S, and pfAT-
Pase6 mutations S538R, Q574P, A623E, N683K and
S769N. The method is based on parallel PCR amplifica-
tion of the target sequences followed by primer exten-
sion mediated mini-sequencing using fluorochrome-
labelled ddNTPs. Subsequent base calling occurs on a
microarray upon sequence specific hybridization [33,34].
Multiplicity of infection (MOI) for each sample was
assessed by determining the number of msp2 genotypes
[31].
Statistical analyses
Data were double entered in EpiData software (version
3.02, Odense, Denmark) and analysis was performed
using STATA software (version 10.1; Stata Corp., Col-
lege Station, Texas). Allele frequencies were calculated
separately for each site for the community samples col-
lected in each year, and separately for the health centre
samples from both, Karimui and South Wosera collected
in 2003. The estimates were very similar to those
obtained using a corresponding Bayesian algorithm [35].
Confidence intervals were calculated using bootstrap
sampling, in each case based on 10,000 bootstrap sam-
ples of the data.
As a measure of genetic differentiation between popu-
lations and sample sets GˆST , the estimate of the GST
statistic [36], obtained using the maximum likelihood
estimates of the allele frequencies, was used. Overall
tests of the null hypothesis that allele frequencies at all
four loci result from a sample from a single population
were carried out using randomization tests of GˆST , in
each case using 10,000 random re-assortments of the
data to sub-populations.
The frequencies of multi-SNP haplotypes were calcu-
lated using the MalHaploFreq programme as described
in detail elsewhere [37]. Haplotype frequencies were
estimated for each of the main combinations of SNPs
possible within each locus. In addition, two-locus haplo-
type frequencies were estimated for SNPs at the loci
involved in SP resistance (i.e., pfdhfr and pfdhps). Locus-
specific comparisons of haplotype frequencies in the dif-
ferent sample sets were carried out using likelihood
ratio tests. The likelihood ratio statistic was computed
as twice the difference between the log-likelihood of the
full model (estimating distinct haplotype frequencies for
each sample set) and that of a model estimating com-
mon haplotype frequencies for all sample sets included
in the comparisons.
Ethical approval
Scientific approval and ethical clearance for the study
was obtained from the Ethikkommission beider Basel
(EKBB) and the Medical Research and Advisory Com-
mittee (MRAC) of the Ministry of Health in PNG.
Informed consent was first requested from all the com-
munities involved and prior to recruitment, individual
consent was obtained from each study participant and
parents or legal guardians.
Results
Characteristics of community survey population
Key characteristics of the sample sets collected from each
site between 2003 and 2005 are given in Table 1. Age dis-
tribution, sex ratio, and mean axillary temperature were
similar between sites, and mean haemoglobin levels were
lower in the high transmission areas of the Wosera and
the North Coast. Microscopic P. falciparum prevalence
rates ranged between 13% and 27%, depending on the
site and the respective year, and from a total of 2013
community blood samples, 695 (34.5%) were found to be
positive for P. falciparum msp2 by PCR and prevalence
rates determined by a positive msp2 PCR ranged from
20% to 41%. MOI determined by msp2 PCR was not
Marfurt et al. Malaria Journal 2010, 9:8
http://www.malariajournal.com/content/9/1/8
Page 4 of 11
significantly different between and within sites over time
(range: 1.5 to 1.8), but the proportion of multiple versus
single infections varied between high and moderate
transmission areas. Multiple infections in either msp2 or
in one or more resistance markers were detected in 436
out of 643 community samples tested, implying the pre-
sence of at least 1,247 parasite clones overall.
In vivo drug efficacy
Clinical and parasitological monitoring up to Day 28
between 2003 and 2005 at all three sites was accom-
plished for a study group of 649 children (Table 1, [30]).
In Karimui, the pooled (AQ+SP and CQ+SP) PCR-cor-
rected TFR tended to decrease over the three-year per-
iod from 28% to 18% and 16%, respectively, but this was
not statistically significant ( 22 = 4.8, p = 0.09). In the
Wosera, the TFR tended to increase, changing from 16%
in 2003 to 22% in 2004, but again this was not statisti-
cally significant ( 12 = 1.2, p = 0.3). In 2004, the TFR at
the North Coast area of Madang was 11.5%.
Allele and haplotype frequencies in community surveys
Analysis of drug resistance mutations was carried out
for 639 (92%) of the community samples. Polymorph-
isms were found in pfmdr1 SNPs N86Y, Y184F and
N1042D, pfcrt SNPs K76T, A220S, N326D, I356L and
S163R, pfdhfr SNPs C59R and S108N, and pfdhps SNPs
A437G and K540E. None of the other SNPs was
detected as mutated allele (Table S1, Additional file 1).
The proportions of samples found to contain mutant
alleles depends on both, the proportion of parasite
clones with the mutation (the mutant allele frequency)
and the MOIs of the samples [35,37]. The estimated
mutant allele frequencies were calculated using the typ-
ing results (Table S1, Additional file 1) and the MOIs
determined by msp2 typing and are given in table S2
(Additional file 2).
High mutant allele frequencies for the CQ relevant
markers in pfcrt were observed for K76T, N326D and
I356L at all three sites (Table S2, Additional file 2). Fre-
quencies of A220S were highest at the North Coast and
lower in Karimui and the Wosera. Mutated pfcrtS163R
alleles were rarely detected and only in Karimui and the
Wosera. Frequencies for pfmdr1N86Y reached quasi
fixed levels in Karimui and at the North Coast, but were
substantially lower in the Wosera. Pfmdr1 polymorph-
isms Y184F and N1042D were never detected in sam-
ples from Karimui and frequencies were low at the
other two sites. Mutant allele frequencies for the SP
relevant markers pfdhfr S108N and C59R were high at
all three sites, but were moderate for pfdhpsA437G and
very low for pfdhpsK540E.
Haplotype frequencies were estimated for the three
SNP combinations pfmdr1N86Y+Y184F+N1042D and
pfcrtK76T+A220S+I356L, and for each of the possible
haplotypes of pfdhfr plus pfdhps arising from the poly-
morphic SNPs (Table S3, Additional file 3).
Comparison between sites
The analysis of between-site genetic variation, based on
comparing the allele frequencies in all community sam-
ples available from each of the three sites, gave a GˆST
value of 0.082, which was greater than the value
obtained in any of the 10,000 randomizations of the
data. This thus corresponds to a P-value < 0.01 suggest-
ing rejection of the null hypothesis that the community
samples come from a single parasite population. This
GˆST value was considerably higher than the values
obtained by comparing between years within sites
(Table 2).
At the pfcrt locus, haplotype frequencies of the wild-
type, single K76T or double K76T+I356L mutants were
observed with frequencies between 0.02 to 0.36 in
Table 2 Statistical tests of differences in allele and haplotype frequencies
GˆST Likelihood ratio tests of differences in haplotype
frequencies
Source of variation Site Locus overall pfcrt pfmdr1 pfdhfr pfdhps
Difference between health
centre and community samples
Karimui test statistic 0.004 6.9 0.0 6.3 0.7
d.f. n.a. 7 7 3 3
P-value 0.3 0.4 1.0 0.1 0.9
South Wosera test statistic 0.011 30.1 2.3 14.3 14.6
d.f. n.a. 7 3 3 3
P-value 0.02 <0.01 0.5 0.002 0.002
Difference between years Karimui test statistic 0.035 44.4 2.5 47.8 21.5
(community samples) d.f. n.a. 14 14 6 6
P-value <0.01 <0.01 1.0 <0.01 0.002
South Wosera test statistic 0.011 44.8 14.6 16.4 12
d.f. n.a. 7 3 3 3
P-value 0.01 <0.01 0.002 0.001 0.007
d.f., degrees of freedom; n.a., not applicable
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Karimui and the Wosera, but were significantly lower in
samples from the North Coast, where the haplotype
with the triple mutation K76T+A220S+I356L was close
to fixation (Table S3, Additional file 3 and Figure 1). At
pfmdr1, the haplotype comprising the single mutation
N86Y predominated at all three sites and was close to
fixation in Karimui and the North Coast, but less fre-
quent (0.68) in the Wosera. Fully wild-type pfdhfr/
pfdhps haplotypes were infrequent at all three sites (0.01
to 0.15) and the predominant haplotype at pfdhfr was
the double mutant S108N+C59R. The pfdhpsA437G
mutation (which always occurred alongside the pfdhfr
double mutation S108N+C59R) was found in a substan-
tial proportion of samples from the Karimui area, but
was much less frequent at the other two sites.
Comparison of clinical and community samples
Comparison of the drug resistance profile in community
and clinical samples was only possible in the Karimui
and South Wosera areas in 2003. In Karimui, the allele
frequencies in health centre samples were close to those
from community samples for the same year (Table S4,
Additional file 4 and Figure 2). In the Wosera, there
were small effects of both, year and source of the sam-
ples on the allele and haplotype frequencies (both GˆST
Figure 1 Single-locus haplotype frequencies in community samples. TFR, Day 28 treatment failure rate; haplotypes are labelled according to
the patterns indicated in Table S3, Additional file 3; labelling is not provided for the superimposed haplotypes with zero or near-zero
frequencies.
Figure 2 Comparison of mutant allele frequencies between clinical and community samples at two study sites in Papua New Guinea
in the year 2003. Error bars denote 95% confidence intervals calculated from 10,000 bootstrap samples of the data.
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values 0.011). Despite the rather similar allele frequen-
cies in community and health centre samples, the differ-
ences in haplotype frequencies between health centre
and community samples were statistically significant for
each locus except pfmdr1 (Table 2).
Comparison between years
In Karimui, there was a significant difference between
years in the vector of allele frequencies in the commu-
nity samples, and the value of 0.035 for GˆST measuring
inter-annual variation was relatively high for each locus
except pfmdr1, where a single haplotype appeared to be
at fixation. The most obvious changes were related to
the allele frequencies of pfcrt N326D, I356L and A220S,
which all decreased over time, as did pfdhpsA437G,
while the frequencies of the pfdhfr mutants increased
(Table S2, Additional file 2). In terms of haplotypes,
pfdhfr and pfdhps appeared to be moving towards fixa-
tion of the same haplotypes as were already fixed at the
North Coast, while there was no indication that any
pfcrt haplotype was moving towards fixation (Table S3,
Additional file 3 and Figure 1).
In the Wosera, the value of GˆST measuring inter-
annual variation was lower (0.011), but the variation in
haplotype frequencies was statistically significant for all
polymorphic loci. While mutations in pfmdr1 appeared
to be relatively stable, those in the other loci appeared to
be moving towards fixation of the same haplotypes as at
the North Coast. Triple mutations in pfcrt increased in
frequency between 2003 and 2004, as did the frequencies
of the pfdhfrS108N+C59R double and pfdhpsA437G sin-
gle mutants (Table S3, Additional file 3 and Figure 1).
Relationship of allele and haplotype frequencies with
treatment failure rates
These differences in allele and single-locus haplotype
frequencies between sites were not reflected in treat-
ment failure rates (TFR) (Figure 3). In particular, the
North Coast site had the lowest TFR, but the highest
frequencies of triple mutants in pfcrt, of double mutants
in pfdhfr and of the main polymorphic mutation in
pfmdr1. Despite the substantial differences in allele and
haplotype frequencies between the Wosera and Karimui,
the average TFRs at these two sites were similar.
The allelic and single-locus haplotype frequencies in
the Wosera seemed to be converging over time with
those of the North Coast parasite population (Figure 1),
while the TFR in the Wosera was increasing (i.e., diver-
ging from that in the North Coast). At the same time,
the general trend in single-locus pfdhfr and pfdhps
mutant haplotype frequencies in Karimui towards the
North Coast values accompanied a decrease in TFRs.
Thus, the allele frequencies in the Wosera and Karimui
could not account for the patterns in TFR. However, a
strikingly different pattern was seen with the two-locus
haplotypes. While the clinical TFR correlated negatively
with the pfdhfr double mutant haplotype when this was
not linked to the pfdhpsA437G mutation, the frequency
of the pfdhfrC59R+S108N/pfdhpsA437G mutant haplo-
type increased with the TFR (Figure 3).
Discussion
The present study was specifically designed to analyse
the relationship between parasite genetics in the com-
munity and in vivo failure rates, but the complexity of
this relationship was not initially appreciated. There is
substantial evidence linking specific genetic markers to
drug resistance in vitro and the presence of genetic
resistance mutations often predicts treatment failure at
the level of the individual patient, but it was observed
that these individual level relationships are not reflected
in straightforward relationships at the population level
between molecular typing results and in vivo tests of
resistance. A number of possible reasons for this discre-
pancy were investigated.
One limitation of many studies is that they have
included only small numbers of SNPs. The chosen SNPs
might prove to be the wrong mutations in the given
population or secondary mutations with indirect relation-
ships to resistance might be important. This was
addressed by using a DNA microarray-based technology
that allowed parallel assessment of many SNPs in several
genes [33]. The analysis of a total of 12 polymorphic
SNPs, as well as a further 21 SNPs that proved to be uni-
formly wild-type, enabled to consider all candidate SNPs
so far identified. The study populations had highly
mutated genes involved in CQR resistance (pfcrt and
mdr1) combined with pfdhfr mutations consistent with a
moderately pyrimethamine resistant phenotype and the
emergence of key mutations in pfdhps. The key CQR
Figure 3 Two locus (pfdhfr plus pfdhps) haplotype frequencies
in community samples. Only haplotypes occurring at polymorphic
frequencies are shown.
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markers pfcrt K76T, N326D and N326D were almost
fixed at all three sites, in keeping with other recent find-
ings [38-40]. Similarly, the high allele frequencies for
pfdhfr S108N and C59R and the resulting high frequency
of the double-mutant haplotype are consistent with a
recent report from East Sepik Province [41]. Despite this
substantial amount of information about each sample,
the allele and single-locus haplotype frequencies could
still not easily be related to in vivo failure rates.
The choice of strategy for sampling the parasite popu-
lation does not seem to be an important determinant of
whether a relationship is seen with treatment failure.
The differences between corresponding genetic profiles
in health facility and community samples were small in
comparison with the differences between sites. In Kari-
mui, the profiles were near identical, and the small dif-
ferences between the two profiles in the Wosera, which
may reflect heterogeneities in access and hence drug
pressure for different parts of the catchment area, are
too small to influence the choice of sampling strategy.
The decision as to whether to sample the community or
health centres should therefore be made on logistic
grounds. Community sampling can be carried out dur-
ing a single short visit to a site, while health facility
sampling is likely to take longer, but may be more con-
venient especially if blood sampling for drug resistance
can be combined with other procedure(s).
A more important factor in being able to predict
treatment failure from parasite genetic data may be the
appropriate analysis of the data. Only by analysing two-
locus pfhfr/pfdhps haplotypes coherent relationships
between the genetic data and TFRs could be seen, cor-
roborating the previous finding that the pfdhfrC59R
+S108N/pfdhpsA437G triple mutant predicts treatment
failure best on individual level in PNG [34]. While this
haplotype was absent in the North Coast and so cannot
account for the treatment failures observed there,
increases in haplotype frequency in the other sample
sets matched remarkably well the increased TFRs. This
is in agreement with studies from Uganda [42] and Laos
[43], that also report pfdhps mutations to be important
markers for unsuccessful treatment response to combi-
nation therapy with CQ plus SP, although the pfdhps
genotype was not indicative for treatment failure with
SP monotherapy in Tanzania [44,45] or Ghana [46].
It has been proposed [47-49] that genetic resistance
can be measured by the ratio between the prevalence of
mutated genotypes to the TFR (the genetic failure index,
GFI). A low, reasonably stable GFI would indicate a
good marker of resistance. The theoretical properties of
GFI are discussed in detail elsewhere [37] where it was
pointed out that the GFI for any given SNP could vary
widely depending on genotypes at other SNPs modulat-
ing the parasites ability to survive therapy. This study
quantified this effect, showing that the relationship
between SNPs and clinical outcome needs to be based
on haplotype frequencies rather than crude prevalence
of a single SNP. The estimation of further multi-locus
haplotype frequencies may be needed before the full
potential of such analysis becomes clear.
Currently, there are technical limitations in the ability
to estimate multi-locus haplotype frequencies. Where
there are no polyclonal infections, haplotype frequencies
can be estimated by simple gene counting. However,
68% of the PCR-positive community samples had multi-
ple msp2 types, implying that only 17% of the parasite
clones could validly be used to estimate allele frequen-
cies by simple gene counting, making this a very ineffi-
cient and imprecise procedure. The estimation of
haplotype frequencies from multi-clone samples using
the MalHaploFreq programme makes use of substan-
tially more information, but with the current implemen-
tation it is not feasible to identify the 3- and 4-locus
haplotype frequencies.
Fortunately, there are two ways of avoiding this limita-
tion. Firstly, to date, most resistance appears to have
arisen through a few single key SNPs such as pfcrtK76T,
pfcrtA220S and pfmdr1N86Y, or by a series of mutations
such as the pfdhfr108-51-59-164 sequence. Thus, most
key multi-locus haplotypes can be characterized at a few
numbers of SNPs (e.g. pfcrtK76T+pfmdr1N86Y,
pfcrtK76T+dhfr I164L, and so on). Secondly, in areas of
moderate to high transmission there is likely to be large
numbers of mixed infections and hence large amounts
of sexual recombination which tends to bring separate
genes into linkage disequilibrium (LD). If the genes are
in LD then the frequency of multi-gene haplotypes can
be obtained simply by multiplying their individual fre-
quencies. Alternately, if mixed infections are rare then
haplotypes can be directly observed in single-clone
infections and MalHaploFreq is not required.
The inter-site differences in TFR need to be under-
stood in the context of the long-term histories of
malaria transmission and drug use at each site, possibly
including locality-specific factors, such as clinical prac-
tice, genetic background of human population and
degree of isolation. After a long history of 4-aminoqui-
noline use, treatment policy against uncomplicated
malaria in PNG changed to combination therapy with
AQ or CQ plus SP only in 2000. Both, the TFR and
allele/haplotype frequencies, including high frequencies
of important markers in pfdhfr and pfdhps, are therefore
the outcomes after only two years of implementation of
combination therapy and are probably highly dependent
on the baseline frequency of resistant mutations at the
time of the policy change.
The sites differed in the frequency of pfcrtA220S cor-
responding to the highly CQ resistant pfcrt quadruple
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mutant haplotype (K76T+N326D+N326D+A220S),
which was close to fixation only at the North Coast.
Similarly, the pfmdr1N86Y mutant was close to fixation
in Karimui and at the North Coast (>92%), but was less
frequent in the Wosera (71%), and the pfmdr1 poly-
morphisms Y184F and N1042D were absent in Karimui.
These genetic differences might simply reflect stochastic
differences in source parasite populations, but they
could also reflect differences in historical drug pressure.
In particular, while pfcrt mutations presumably reflect a
history of CQ use, SNPs in pfmdr1 conferring both,
resistance to CQ and altered sensitivity to other drug
classes, including quinine (which was used for treatment
of severe malaria in PNG), arylaminoalcohols and arte-
misinin derivates [37,50], are presumably selected by
exposure to these. The fixation of a highly CQ resistant
haplotype at the North Coast may reflect a history of
very high CQ pressure due to good health care provi-
sion as well as easy (and unregulated) access to drugs in
the nearby town of Madang. In contrast, former 4-ami-
noquinoline use is assumed to be lower in the remote
regions in Karimui and the Wosera, so it is possible that
the North Coast pattern is one towards which the others
are progressing as a result of drug pressure, yet the
North Coast had the lowest TFR. However, former drug
pressure with anti-folates in the course of previous mass
drug administration campaigns was higher in the two
more remote regions [51,52], so a reservoir of anti-folate
resistance may have been present there for a long time.
Parasite CQR at all three sites may have reached a pla-
teau, while resistance to SP evolved at a different speed
depending on both, historical and current anti-folate
drug pressure. The frequency of the pfcrtA220S muta-
tion increased in the Wosera between 2003 and 2004,
most likely as a consequence of inappropriate drug use
exerted on a large and heterogeneous parasite popula-
tion. This arose because of 1) health systems manage-
ment problems in the area, which lead to an
undersupply with SP (local health extension officer at
the Kunjingini health centre, personal communication)
and 2) drug consumption outside health facilities which
was relatively frequent by local standards (10% and 12%
of the survey populations in 2003 and 2004, respec-
tively) with AQ or CQ monotherapy distributed by
inadequately trained community health workers. These
factors may have further enhanced CQR leading to a
reduced capacity of CQ to protect SP. Within the same
time period, decreasing trends of TFRs were accompa-
nied by decreasing frequencies of pfcrtA220S and
pfdhpsA437G in Karimui. Health care provision gener-
ally improved due to better medical supply to this
remote highland area and the study increased awareness
of malaria. The result appears to have been effective
delivery of combination therapy to a higher proportion
of malaria cases, acting on a relatively small parasite
population, therefore preventing the further develop-
ment and spread of parasite resistance in this moderate
transmission area [53,54].
The in vivo and molecular data suggest that in the
current first-line regimen in PNG, SP, and more specifi-
cally sulphadoxine is the effective component. Hence,
molecular monitoring of resistance to this component is
important under constant treatment policy. However,
significant levels of in vivo failure are a strong argument
for the introduction of an artemisinin-based combina-
tion regimen. Once such a regimen is introduced, rapid,
easy-to-use and affordable surveillance systems will be
needed to monitor emergence and spread of resistance
to the components of the new combination. At the
same time, surveillance of resistance to withdrawn drugs
should also be continued, with the prospect that
decreases in resistance may make it possible to reuse
one or more of these safe and cheap drugs as partner
compounds in combination regimens [55,56].
Conclusions
In summary, despite there being considerable interest in
using molecular data to predict drug failure rates, and
hence inform and guide policy choice [5,57], the current
analyses showed that the relationship was not as simple
as might be hoped. Molecular drug resistance profiles
were similar in parasites from community and clinical
samples, but these did not closely reflect the longitudi-
nal and geographical variation in in vivo drug efficacy
observed at health centres. The data confirm that the
genetic drug resistance background of the parasite is
only one of many factors determining clinical outcome
and one which has evolved differently according to epi-
demiological characteristics as well as history and pat-
terns of drug use in a given area. In particular it was
shown that (i) using genetic markers to predict failure
rates is much better if based on haplotype frequencies
rather than crude prevalence of individual SNPs, and (ii)
SNP marker sets will have to be constantly updated and
adapted to future monitoring purposes, such as the
inclusion of markers for newly introduced or withdrawn
drug classes. Finally, this community-based molecular
monitoring approach will have to be further evaluated
in geographical areas at both extremes of transmission
intensity and different drug use patterns (e.g. rural ver-
sus urban areas) in order to test its validity as a comple-
mentary resistance monitoring tool.
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